Inventor · disambiguated record
Johannes H. Voigt
Also filed as: VOIGT JOHANNES · VOIGT JOHANNES H
31 granted patents·13 pending applications·203 citations·filing 2001–2025
97Inventor score
Files withFOGHORN THERAPEUTICS INC18SCHERING CORP10ZHU ZHAONING4GILEAD SCIENCES INC2SHIPPS JR GERALD W2
Top patents by PatentIndex Score
44 records- 0195US11560381B1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2022·Granted Jan 24, 2023·12 cites·12 claims
- 0295US11414416B1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Granted Aug 16, 2022·16 cites·15 claims
- 0395US7763609B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2007·Granted Jul 27, 2010·38 cites·12 claims
- 0494US11851445B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·9 cites·6 claims
- 0593US11352329B2HIV protease inhibitorsGILEAD SCIENCES INC·Filed 2020·Granted Jun 7, 2022·3 cites·5 claims
- 0692US11787800B2BRD9 degraders and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Granted Oct 17, 2023·3 cites·24 claims
- 0790US7868000B2Aspartyl protease inhibitorsSCHERING CORP·Filed 2006·Granted Jan 11, 2011·18 cites·45 claims
- 0888US7700603B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2005·Granted Apr 20, 2010·9 cites·8 claims
- 0986US7973067B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2008·Granted Jul 5, 2011·6 cites·22 claims
- 1086US7910590B2Cyclic amine bace-1 inhibitors having a heterocyclic substituentSCHERING CORP·Filed 2009·Granted Mar 22, 2011·8 cites·31 claims
- 1185US8278334B2Cyclic amine BACE-1 inhibitors having a benzamide substituentCUMMING JARED N·Filed 2009·Granted Oct 2, 2012·7 cites·10 claims
- 1284US7592348B2Heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2004·Granted Sep 22, 2009·16 cites·41 claims
- 1383US10774053B2HIV protease inhibitorsGILEAD SCIENCES INC·Filed 2018·Granted Sep 15, 2020·4 cites·17 claims
- 1483US8012953B2Macrocyclic beta-secretase inhibitorsSCHERING CORP·Filed 2009·Granted Sep 6, 2011·5 cites·30 claims
- 1583US7812013B2Macrocyclic heterocyclic aspartyl protease inhibitorsSCHERING CORP·Filed 2006·Granted Oct 12, 2010·5 cites·12 claims
- 1682US8557798B2Macrocyclic heterocyclic aspartyl protease inhibitorsISERLOH ULRICH·Filed 2009·Granted Oct 15, 2013·5 cites·11 claims
- 1780US7662816B2Cyclic amine BACE-1 inhibitors having a benzamide substituentSCHERING CORP·Filed 2004·Granted Feb 16, 2010·11 cites·25 claims
- 1879US7652003B2Macrocyclic β-secretase inhibitorsSCHERING PLOUGH CORP·Filed 2005·Granted Jan 26, 2010·5 cites·24 claims
- 1977US8242112B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2011·Granted Aug 14, 2012·2 cites·4 claims
- 2076US8759357B2Inhibitors of fatty acid binding protein (FABP)SHIPPS JR GERALD W·Filed 2010·Granted Jun 24, 2014·6 cites·8 claims
- 2176US7259142B2Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and useUS HEALTH·Filed 2005·Granted Aug 21, 2007·1 cites·7 claims
- 2274US12351579B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Granted Jul 8, 2025·0 cites·18 claims
- 2374US8178513B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2009·Granted May 15, 2012·1 cites·13 claims
- 2472US7598250B2Cyclic amine BACE-1 inhibitors having a heterocyclic substituentSCHERING CORP·Filed 2004·Granted Oct 6, 2009·5 cites·34 claims
- 2572US6977241B2SH2 domain binding inhibitorsUS HEALTH·Filed 2001·Granted Dec 20, 2005·3 cites·47 claims
- 2672US2024166668A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2771US8815875B2Inhibitors of fatty acid binding protein (FABP)SHIPPS JR GERALD W·Filed 2009·Granted Aug 26, 2014·2 cites·11 claims
- 2871US2024150348A1Brd9 degraders and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2970US8357682B2Gamma secretase modulatorsZHU ZHAONING·Filed 2008·Granted Jan 22, 2013·1 cites·37 claims
- 3067US2023142883A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3165US2023066136A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3263US8889683B2Substituted quinoxalines as inhibitors of fatty acid binding proteinCHENG CLIFFORD·Filed 2011·Granted Nov 18, 2014·2 cites·9 claims
- 3362US2025304596A1Pyrazine derivatives and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3461US8778980B2Heterocyclic aspartyl protease inhibitorsZHU ZHAONING·Filed 2012·Granted Jul 15, 2014·0 cites·15 claims
- 3561US2025302832A1Pyrazine derivatives and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3659US2025304572A1Heterocyclic glp-1r agonistsBIOMEA FUSION INC·Filed 2025·Application pending·0 cites
- 3757US2024376121A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3854US2024024488A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3954US2023416248A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4053US2023348452A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4148US12391686B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Granted Aug 19, 2025·0 cites·22 claims
- 4248US12384776B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Granted Aug 12, 2025·0 cites·17 claims
- 4348US2023065463A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4442US2008031812A1Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates, thereof, compositions and methods of synthesis and useGOVERNMENT OF THE USA REPRESEN·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Johannes H. Voigt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →